Drugs in Dev. Ophthalmology
Phase III
Italy 
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SIFI Receives Positive Opinion for Orphan Drug Designation for Polihexanide
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 22, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
SIFI Receives Positive CHMP Opinion for AKANTIOR in Acanthamoeba Keratitis
Details : Akantior® (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 31, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Avanzanite’s AKANTIOR® Gets Positive CHMP Opinion and Expands into 26 European Countries
Details : Akantior (polihexanide) is an investigational anti-amoebic polymer that recieved positive opinion from European Medicines Agency for the treament of acanthamoeba keratitis.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
March 06, 2024
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : 87% of patients receiving AKANTIOR® in the Phase 3 Trial were medically cured within a median duration of 4 months compared to 55% with the treatment protocols used in real-world clinical practice today.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
October 13, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Durbin
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKANTIOR® (polihexanide) stands to become first approved drug for the treatment of acanthamoeba keratitis in the world. It is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan Acanthamoeba.
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
July 06, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Durbin
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : AKANTIOR (polihexanide) stands to become the first approved drug for the treatment of acanthamoeba keratitis in the world. Polihexanide, a New Chemical Entity (NCE), is an anti-amoebic polymer that acts on both the trophozoites and cysts of the protozoan...
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
May 16, 2022
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : SIFI is conducting a multi-center randomized, double-masked, and active-controlled Phase III trial designed to evaluate the efficacy, safety, and local tolerability of polihexanide 0.08% compared to a combination of polihexanide 0.02% and 0.1% propamidin...
Product Name : Akantior
Product Type : Other Small Molecule
Upfront Cash : Inapplicable
November 19, 2020
Lead Product(s) : Polyhexanide
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Inapplicable
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Study Phase : Phase III
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
NTC Grants License and Distribution Rights in Israel to Taro Pharmaceutical Industries
Details : NTC Srl has granted exclusive license and distribution rights to one of its R&D products to Taro Pharmaceutical. The product combines a quinolone antibiotic with an anti-inflammatory steroid in eye drops intended to provide an appropriate treatment for p...
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Undisclosed
June 17, 2020
Lead Product(s) : Levofloxacin,Dexamethasone
Therapeutic Area : Ophthalmology
Highest Development Status : Phase III
Sponsor : Taro Pharmaceutical Industries
Deal Size : Undisclosed
Deal Type : Licensing Agreement
Reset All
